Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss ...

The decision of the General Court of the European Union in the Pfizergate case would allow the European Commission to ...

(Reuters) -Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ETCompany ParticipantsAlbert Bourla - Chairman of ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services terminated a contract with drugmaker Moderna to develop an mRNA bird flu ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...